The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix
Uma Singh, Neetu Ahirwar, Anju Kumari Rani, Nisha Singh, Pushplata Sankhwar, Sabuhi Qureshi, Uma Singh, Neetu Ahirwar, Anju Kumari Rani, Nisha Singh, Pushplata Sankhwar, Sabuhi Qureshi
Abstract
Objective: A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix.
Method: Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m(2) and paclitaxel 135 mg/m(2) on day 1 and repeated at 14 days' interval for up to a maximum of three courses.
Results: Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed.
Conclusion: The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.
Keywords: Cervical cancer; Downstaging; Neoadjuvant chemotherapy.
Figures
Source: PubMed